Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 4Completed 4Not yet recruiting 3Unknown 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 36Cholangiocarcinoma 11Carcinoma, Renal Cell 10Stomach Neoplasms 5Liver Neoplasms 5Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Uterine Cervical Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasm Metastasis 2Liver Diseases 2Kidney Neoplasms 2Cirrhosis, Familial, with Pulmonary Hypertension 2Breast Neoplasms 2Advanced Solid Tumor 2von Hippel-Lindau Disease 1Urogenital Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumor, Adult 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Penile Neoplasms 1

Interventions

Gemcitabine 23Cisplatin 22durvalumab 13pembrolizumab 8Oxaliplatin 7Capecitabine 7Fluorouracil 6Leucovorin 5Bevacizumab 5lenvatinib 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Nivolumab 3Liquid Biopsy 3Injections 3Folfox protocol 3zanidatamab 2trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2ivosidenib 2futibatinib 2apatinib 2Trastuzumab 2Taxes 2Irinotecan 2Immune Checkpoint Inhibitors 2Drug Therapy 2Carboplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Biliary Tract Neoplasms × lenvatinib × Clear all
NCT05775159 2026-04-17

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

AstraZeneca

Phase 2 Recruiting
294 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT07530445 2026-04-15

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

Sun Yat-sen University

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

CHA University

Recruiting
100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Peking Union Medical College Hospital

Phase 2 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡